trustme.bro/r/…
✓ checked
trust me, bro:
here is the receipt.
the claim

Hereditary cancer risk can be accurately estimated using genetic and family history models.

the verdict
SUPPORTED
the evidence backs this
Recorded sources
10 sources for · 0 against

Counts group repeated records of the same source within each side. They do not measure evidence strength or source independence.

Multiple clinical and genetic studies demonstrate that hereditary cancer risk can be effectively estimated using combined genetic models, polygenic risk scores, and family history data.

The analysis

The retrieved literature robustly supports the claim that hereditary cancer risk can be accurately estimated using genetic and family history models. Numerous studies across different cancers (breast, ovarian, cardiometabolic conditions, and general panels) demonstrate that combining genetic variants (such as polygenic risk scores and pathogenic mutations) with family history and clinical variables improves risk stratification, predictive accuracy, and clinical management. There are no papers refuting this consensus.

Evidence for · 10
Recorded source metadata

G. Vasileiou, M. J. Costa, Christopher Long, Iris R. Wetzler, Juliane Hoyer, C. Kraus, B. Popp, J. Emons, M. Wunderle, E. Wenkel, M. Uder, M. Beckmann, S. Jud, P. Fasching, A. Cavallaro, A. Reis, M. Hammon. Breast MRI texture analysis for prediction of BRCA-associated genetic risk. 2020. https://doi.org/10.1186/s12880-020-00483-2

Demonstrates that combining genetic factors, imaging, and family cancer history effectively predicts hereditary breast cancer risk.

See more details
More for · 9
Recorded source metadata

S. Stiller, S. Drukewitz, K. Lehmann, J. Hentschel, V. Strehlow. Clinical Impact of Polygenic Risk Score for Breast Cancer Risk Prediction in 382 Individuals with Hereditary Breast and Ovarian Cancer Syndrome. 2023. https://doi.org/10.3390/cancers15153938

Shows that incorporating polygenic risk scores into standard genetic testing improves breast cancer risk stratification and clinical recommendations.

Recorded source metadata

Patel K, Dite GS, Spaeth EL, Rosner BA. Validation of a Clinical and Polygenic Risk Prediction Model for Ovarian Cancer in the Nurses' Health Study.. 2026. https://doi.org/10.1158/1940-6207.capr-24-0528

Validates a combined clinical and polygenic risk prediction model for ovarian cancer screening and prevention.

Recorded source metadata

Onyenobi E, Oyibo K, Zhong M, Adebamowo SN. Evaluating the impact of family history and polygenic risk scores on cardiometabolic disease risk.. 2026. https://doi.org/10.1186/s12916-026-04666-6

Indicates that both family history and polygenic risk scores are significantly associated with disease risk and enhance risk stratification when integrated.

Recorded source metadata

Tüchler A, Grohs L, Volk A, Aretz S. Polygenic risk scores in cancer.. 2026. https://doi.org/10.1515/medgen-2026-3011

Notes that polygenic risk scores refine cancer risk prediction beyond family history and age across multiple cancer types.

Recorded source metadata

Liang JW, Idos GE, Hong C, Shannon KM, Bear LM, Pichardo JM, Guan Z, McCarthy AM, Ford JM, Kurian AW, Gruber SB, Braun D, Parmigiani G. Evaluating a Mendelian Risk Prediction Model That Aggregates Across Genes and Cancers.. 2026. https://doi.org/10.1002/gepi.70038

Evaluates Mendelian risk prediction models that aggregate across genes and family histories to accurately identify heritable cancer susceptibility.

Recorded source metadata

Corredor JL, Li R, Dodd-Eaton EB, Casey J, Woodson AH, Nguyen NH, Peng G, Gutierrez AM, Arun BK, Wang W. Performance of LFSPRO prediction in TP53 mutation status for prospectively collected probands.. 2026. https://doi.org/10.1016/j.ajhg.2026.03.014

Demonstrates that family-history-based Mendelian models like LFSPRO provide strong discriminatory performance in predicting hereditary cancer risk.

Recorded source metadata

Chen X, Ke J, Flynn L, Parmigiani G, Braun D. Web-Based User Interface for Fam3PRO: A Multigene, Multicancer Risk Prediction Model for Families With Cancer History.. 2026. https://doi.org/10.1200/cci-25-00332

Presents validated multigene, multicancer Mendelian models that estimate patient risk of carrying pathogenic variants based on family history and genetic factors.

Recorded source metadata

Gu W, Xu C, Fu J, Lei H, Khan NU, Lei R, Chen X, Wang XJ, Chen T. Clinical predictors of <i>BRCA1/2</i> P/LP variants for high-risk breast cancer patients in China: <i>HBRCA-risk prediction</i>.. 2026. https://doi.org/10.3389/fonc.2026.1779548

Shows that clinicopathology-based models incorporating family history and genetic markers effectively predict hereditary breast cancer risk in clinical cohorts.

Recorded source metadata

Sun Y, Simmons T, Li JL, Jamal A, Manirakiza AVC, Pruss D, Ratzel S, Olopade OI, Gutin A, Hughes E, Huo D. Polygenic Risk Scores for Breast Cancer Among African American Women With High Risk.. 2026. https://doi.org/10.1001/jamanetworkopen.2026.19285

Evaluates polygenic risk scores alongside family history to provide accurate breast cancer risk stratification in diverse populations.

The paper trail · every fact has a biography
first checked02 Aug 2026
judged → SUPPORTED · 8202 Aug 2026
Anyone with this link can read the claim and its public receipt, including any personal information in that text. Open permanent receipt.
Check your own claim
Challenge the receipt
Requests are recorded for review. This does not start an automatic check or guarantee a response time.
trust me, bro: win the argument, pass the class, survive peer review.

Citation formatting by citeproc-js (Frank Bennett) and the Citation Style Language project. Source and licenses.

This receipt is an automated verdict against our published method · not an opinion about any author or publication.
Terms · Privacy · How verdicts work · Dispute this receipt